Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 68.1%

Neg 68.1% Neu 0% Pos 0%

Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $22 to $20.